About this trial
Cardiogenic shock is the most severe manifestation of acute heart failure and remains the leading cause of death in patients hospitalised with acute myocardial infarction.
Cardiogenic shock is a well-known and potent trigger of the immune response, ischemia/reperfusion organ damage, hemolysis and release of free hemoglobin. The activation of immune cells leads to the release of cytokines and inflammatory mediators such as IL-6, IL-8, activated complement and others. As a result of myocardial ischaemia and reperfusion injury, a multiorgan dysfunction syndrome may develop.
The Efferon CT hemoadsorption device effectively removes cytokines and other pro-inflammatory molecules (≤55 kDa). This study evaluates whether this blood-filtering therapy can prevent organ failure in acute myocardial infarction patients with cardiogenic shock by eliminating inflammation-inducing mediators.
Eligibility criteria
Qualifiers
Not more than 4 hours after diagnosis Cardiogenic shock complicating acute myocardial infarction
Stages B - C of cardiogenic shock according to SCAI
Patient condition allows treatment with Efferon® CT device for at least 4 hours
SOFA score 12 or less
Disqualifiers
Broken-heart syndrome (takotsubo cardiomyopathy)
Postcardiotomy cardiogenic shock
Acute myocardial infarction within the last 4 weeks
Myocarditis
Trial design
Treatments tested in this trial
- Efferon CT